Detalhe da pesquisa
1.
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution.
Mol Cell
; 79(3): 472-487.e10, 2020 08 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32531202
2.
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.
Genes Dev
; 33(5-6): 310-332, 2019 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30804224
3.
Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
Proc Natl Acad Sci U S A
; 120(3): e2214350120, 2023 01 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36634146
4.
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Genes Dev
; 31(1): 18-33, 2017 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28096186
5.
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
BMC Cancer
; 24(1): 446, 2024 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38600471
6.
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Lancet Oncol
; 24(7): 733-743, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37352875
7.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36335217
8.
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
BMC Cancer
; 23(1): 896, 2023 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37741968
9.
An on-call escape room: Escaping the monotony of a didactic induction for doctors.
Med Teach
; 45(4): 375-379, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36308726
10.
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.
Lancet Oncol
; 23(6): 748-757, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35617989
11.
Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.
Gastroenterology
; 161(4): 1229-1244.e9, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34147519
12.
Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A.
Nat Immunol
; 11(11): 1039-46, 2010 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-20890286
13.
Lag3: From Bench to Bedside.
Cancer Treat Res
; 183: 185-199, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35551660
14.
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Br J Cancer
; 125(4): 510-519, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34040175
15.
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Br J Cancer
; 124(10): 1661-1669, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33723392
16.
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
BMC Cancer
; 21(1): 3, 2021 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33402121
17.
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
BMC Cancer
; 21(1): 642, 2021 May 29.
Artigo
Inglês
| MEDLINE | ID: mdl-34051732
18.
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
BMC Cancer
; 21(1): 851, 2021 Jul 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34301221
19.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32961119
20.
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Br J Cancer
; 123(6): 885-897, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32713938